A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

Clinical trial NCT05346952 · UNKNOWN

Trial details

NCT number: NCT05346952
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Advanced Non-squamous Non-small Cell Lung Cancer

Start date: 2022-01-25
Primary completion: 2023-12-01
Enrollment: 390

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.